It seems like your message might be incomplete or empty. Could you please provide more details or clarify what you're asking for? I'm here to help with any questions or tasks you have! .
ByAinvest
Monday, Nov 10, 2025 10:27 am ET1min read
IFRX--
InflaRx surged 35.37% intraday trading, driven by positive Phase 2a clinical data for INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The trial showed 29/31 HS patients and 30/31 CSU patients experienced rapid reduction in abscesses/nodules with no safety signals, including a 13.7-point average decrease in UAS7 scores for CSU patients (15.4 points in severe cases) and no serious adverse reactions.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet